Hims & Hers cuts its adjusted EBITDA outlook even as revenue jumps 49% to $890M
The telehealth company lowered its 2026 adjusted EBITDA forecast to $257 million to $277 million, swung to a $33 million net loss and disclosed paid agreements tied to new director Andrew Huberman.

Hims & Hers Health's revenue growth is speeding up. Its forecast for adjusted EBITDA is going the other way.
The telehealth company said Nov. 9 that third-quarter revenue rose 49% to $890.4 million from $599.0 million, which Yemi Okupe, chief financial officer, called its second straight quarter of accelerating growth. In the same release, Hims cut its full-year adjusted EBITDA forecast to $257 million to $277 million from the $275 million to $325 million it gave in August.
Why it matters: The midpoint of the new range is $33 million, or 11%, below the old one, and Hims forecast an adjusted EBITDA margin of 8% to 9% for the year. Gross margin fell to 57% from 74% in the quarter, and the company swung to a net loss of $33.0 million from net income of $15.8 million a year earlier.
Where the growth came from
Much of the growth came from outside the U.S. Revenue from the rest of the world rose 321% to $233.3 million, or about 26% of the total, up from about 9% a year earlier. U.S. revenue grew 21% to $657.1 million.
Subscribers rose 13% to about 2.79 million, and monthly revenue per average subscriber climbed 30% to $105.
Okupe said the company was "intentionally pacing marketing spend ahead of several planned expansions" to its platform in the fourth quarter. Marketing expense rose to $247.3 million from $232.2 million, which works out to about 28% of revenue, down from about 39%. The release did not explain the drop in gross margin.
The numbers behind the cut
Adjusted EBITDA, as the company defines it, rose to $82.4 million from $78.4 million, but the margin fell to 9% from 13%. The company's adjustments included $35.4 million of acquisition, transaction and earn-out costs in the quarter. Operating cash flow fell to $65.4 million from $148.7 million, and free cash flow to $26.0 million from $79.4 million.
Third-quarter revenue and adjusted EBITDA both landed within the ranges Hims had forecast in August, of $880 million to $900 million and $75 million to $95 million.
Hims narrowed its 2026 revenue forecast to $3.13 billion to $3.15 billion from $3.1 billion to $3.3 billion, which lowers the midpoint by $60 million. For the fourth quarter, it projected revenue of $875 million to $895 million and adjusted EBITDA of $70 million to $90 million.
A new director with paid agreements
In a separate filing the same day, Hims disclosed that its board expanded to 10 seats on Nov. 4 and appointed Dr. Andrew Huberman, 51. The board determined he is not independent under New York Stock Exchange standards, and he is not expected to join any committees.
On Nov. 5, a Hims subsidiary signed a two-year brand marketing and advisory agreement that pays Huberman $3.5 million a year, plus up to $1 million a year if he makes short-form videos for its paid advertising. The subsidiary also agreed to pay Scicomm Media, which Huberman co-founded and co-owns, $5 million a year for podcast advertising for up to three years. The filing put the value of Huberman's interest in that contract at about $2.1 million a year.
Taken together, the two agreements commit Hims to as much as $9.5 million a year, on top of his director pay: a $50,000 annual cash retainer and an equity award valued at $250,000 a year, prorated for his first term, according to the filing. The fourth quarter is when Okupe said the planned platform expansions will arrive. The release did not say what they are.



